Postmenopausal Hormone Replacement Therapy for Primary Prevention of Chronic Conditions: Summary of Evidence (continued)

You Are Here: AHRQ Home > Clinical Information > U.S. Preventive Services Task Force (USPSTF) > Guide to Clinical Preventive Services, 2001-2004 > Hormone Replacement Therapy > Summary of Evidence

References (continued)

70. Devor M, Barrett-Connor E, Renvall M, et al. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 1992;92(3):275-82.

71. Sillero-Arenas M, Delgado-Rodriguez M, Rodigues-Canteras R, et al. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol 1992;79(2):286-94.

72. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 1993;168(5):1473-80.

73. World Health Organization. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1997;349(9060):1202-9.

74. Armstrong BK. Oestrogen therapy after the menopause: boon or bane? Med J Aust 1988;148(5):213-4.

75. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991;151(1):67-72.

76. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117(12):1016-37.

77. Steinberg KK, Smith SJ, Thacker SB, et al. Breast cancer risk and duration of estrogen use: the role of study design in meta-analysis. Epidemiology 1994;5(4):415-21.

78. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332(24):1589-93.

79. La Vecchia C, Negri E, D'Avanzo B, Parazzini F, Gentile A, Franceschi S. Oral contraceptives and non-contraceptive oestrogens in the risk of gallstone disease. J Epidemiol Community Health 1992;46:234-236.

80. Magnusson C, Baron JA, Correia N, et al. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 1999;81(3):339-44.

81. Ross RK, Paganini-Hill A, Wan PC, et al. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92(4):328-32.

82. Henrich JB, Kornguth PJ, Viscoli CM, et al. Postmenopausal estrogen use and invasive versus in situ breast cancer risk. J Clin Epidemiol 1998;51(12):1277-83.

83. Newcomb PA, Longnecker MP, Storer BE, et al. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women [published erratum appears in Am J Epidemiol 1996;143(5);527]. Am J Epidemiol 1995;142(8):788-95.

84. Stanford JL, Weiss NS, Voigt LF, et al. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995;274(2):137-42.

85. Tavani A, Braga C, La Vecchia C, et al. Hormone replacement treatment and breast cancer risk: an age-specific analysis. Cancer Epidemiology, Biomarkers & Prevention 1997;6(1):11-14.

86. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336(25):1769-75.

87. Weinstein AL, Mahoney MC, Nasca PC, Hanson RL, Leske MC, Varma AO. Oestrogen replacement therapy and breast cancer risk: a case-control study. Int J Epidemiol 1993;22(5):781-9.

88. Yang CP, Daling JR, Band PR, Gallagher RP, White E, Weiss NS. Noncontraceptive hormone use and risk of breast cancer. Cancer Causes & Control 1992;3(5):475-9.

89. Brinton LA, Brogan DR, Coates RJ, Swanson CA, Potischman N, Stanford JL. Breast cancer risk among women under 55 years of age by joint effects of usage of oral contraceptives and hormone replacement therapy. Menopause 1998;5(3):145-51.

90. Fioretti F, Tavani A, Bosetti C, et al. Risk factors for breast cancer in nulliparous women. Br J Cancer 1999;79(11-12):1923-8.

91. Lipworth L, Katsouyanni K, Stuver S, Samoli E, Hankinson SE, Trichopoulos D. Oral contraceptives, menopausal estrogens, and the risk of breast cancer: a case-control study in Greece. Int J Cancer 1995;62(5):548-51.

92. Persson I, Thurfjell E, Bergstrom R, Holmberg L. Hormone replacement therapy and the risk of breast cancer. Nested case-control study in a cohort of Swedish women attending mammography screening. Int J Cancer 1997;72(5):758-61.

93. Levi F, Lucchini F, Pasche C, La Vecchia C. Oral contraceptives, menopausal hormone replacement treatment and breast cancer risk. Eur J Cancer Prev 1996;5(4):259-66.

94. Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283(4):485-91.

95. Persson I, Yuen J, Bergkvist L, et al. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy: long-term follow-up of a Swedish cohort. Int J Cancer 1996;67(3):327-32.

96. Willis DB, Calle EE, Miracle-McMahill HL, et al. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes & Control 1996;7(4):449-57.

97. Ettinger B, Friedman GD, Bush T, et al. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 1996;87(1):6-12.

98. Sellers TA, Mink PJ, Cerhan JR, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 1997;127(11):973-80.

99. Schairer C, Gail M, Byrne C, et al. Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst 1999;91(3):264-70.

100. Sourander L, Rajala T, Raiha I, Makinen J, Erkkola R, Helenius H. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet 1998;352(9145):1965-9.

101. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332(24):1589-93.

102. Gapstur SM, Potter JD, Sellers TA, Folsom AR. Increased risk of breast cancer with alcohol consumption in postmenopausal women. Am J Epidemiol 1992;136(10):1221-31.

103. Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study [see comments]. JAMA 1999;281(22):2091-7.

104. Risch HA, Howe GR. Menopausal hormone usage and breast cancer in Saskatchewan: a record-linkage cohort study. Am J Epidemiol 1994;139(7):670-83.

105. Schairer C, Byrne C, Keyl PM, Brinton LA, Sturgeon SR, Hoover RN. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes & Control 1994;5(6):491-500.

106. Schuurman AG, van den Brandt PA, Goldbohm RA. Exogenous hormone use and the risk of postmenopausal breast cancer: results from The Netherlands Cohort Study. Cancer Causes & Control 1995;6(5):416-24.

107. Folsom AR, Mink PJ, Sellers TA, Hong CP, Zheng W, Potter JD. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health 1995;85(8 Pt 1):1128-32.

108. Harding C, Knox WF, Faragher EB, Baildam A, Bundred NJ. Hormone replacement therapy and tumour grade in breast cancer: prospective study in screening unit [published erratum appears in BMJ 1996 Jul 27;313(7051):198]. Br Med J 1996;312(7047):1646-7.

109. Lando JF, Heck KE, Brett KM. Hormone replacement therapy and breast cancer risk in a nationally representative cohort. Am J Prev Med 1999;17(3):176-80.

110. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999;106(5):574-82.

111. Grady D, Gebretsadik T, Ernster VL, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304-13.

112. Hammond C, Jelovsek F, Lee K, Creasman W, Parker R. Effects of long-term estrogen replacement therapy. II. Neoplasia. Am J Obstet Gynecol 1979;133:537-47.

113. Gambrell R Jr, Massey F, Casteneda T, Ugenas A, Ricci C, Wright J. Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstet Gynecol 1980;55:732-8.

114. Persson I, Adami HO, Bergkvist L, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 1989;298:147-51.

115. Voigt L, Weiss N, Chu J, Daling J, McKnight B, vanBelle G. Progestogen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991;338:274-77.

116. Jick S, Walker A, Jick H. Estrogens, progesterone, and endometrial cancer. Epidemiology 1993;4:20-4.

117. Brinton L, Hoover R. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. Obstet Gynecol 1993;81:265-71.

118. Wells G, Tugwell P, Shea B, et al. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endo Reviews 2002;23(4):529-39.

119. Torgerson D, Bell-Syer S. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001;285(22):2891-7.

120. Komulainen MH, Kroger H, Tuppurainen MT, et al. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial. Maturitas 1998;31(1):45-54.

121. Mosekilde L, Beck-Nielsen H, Sorensen OH, et al. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women: results of the Danish Osteoporosis Prevention Study. Maturitas 2000;36:181-93.

122. Cauley JA, Black DM, Barrett-Connor E, et al. Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS). Am J Med 2001;110(6):442-50.

123. Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1995;122(1):9-16.

124. Kiel DP, Felson DT, Anderson JJ, et al. Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study. N Engl J Med 1987;317(19):1169-74.

125. Maxim P, Ettinger B, Spitalny GM. Fracture protection provided by long-term estrogen treatment. Osteoporos Int 1995;5(1):23-9.

126. Naessen T, Persson I, Adami HO, et al. Hormone replacement therapy and the risk for first hip fracture: a prospective, population-based cohort study. Ann Intern Med 1990;113(2):95-103.

127. Grodstein F, Stampfer MJ, Falkeborn M, et al. Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women. Epidemiology 1999;5(10):476-80.

128. Hoidrup S, Gronbaek M, Gottschau A, et al. Alcohol intake, beverage preference, and risk of hip fracture in men and women. Copenhagen Centre for Prospective Population Studies. Am J Epidemiol 1999;149(11):993-1001.

129. Janowsky JS, Chavez B. Sex steroids modify working memory. J Cogn Neurosci 2000;12(3):407-14.

130. Shaywitz SE, Shaywitz BA, Pugh KR, et al. Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. JAMA 1999;281(13):1197-202.

131. Polo-Kantola P, Portin R, Polo O, et al. The effect of short-term estrogen replacement therapy on cognition: a randomized, double-blind, cross-over trial in postmenopausal women. Obstet Gynecol 1998;91(3):459-66.

132. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 1992;17(5):485-95.

133. Ditkoff EC, Crary WG, Cristo M, et al. Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol 1991;78(6):991-5.

134. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology 1988;13(4):345-57.

135. Fedor-Freybergh P. The influence of oestrogens on the wellbeing and mental performance in climacteric and postmenopausal women. Acta Obstetricia et Gynecologica Scandinavica - Supplement 1977;64:1-91.

136. Hackman BW, Galbraith D. Replacement therapy and piperazine oestrone sulphate ('Harmogen') and its effect on memory. Current Medical Research & Opinion 1976;4(4):303-6.

137. Vanhulle G, Demol P. A double-blind study into the influence of estriol on a number of psychological tests in post-menopausal women. In: van Keep PA, et al., ed. Consensus on Menopause Research. Lancaster, Eng.: MTP; 1976.

138. Rice MM, Graves AB, McCurry SM, et al. Postmenopausal estrogen and estrogen-progestin use and 2-year rate of cognitive change in a cohort of older Japanese American women: the Kame Project. Arch Intern Med 2000;160(11):1641-9.

139. Yaffe K, Haan M, Byers A, et al. Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. Neurology 2000;54(10):1949-54.

140. Carlson LE, Sherwin BB. Relationships among cortisol (CRT), dehydroepiandrosterone-sulfate (DHEAS), and memory in a longitudinal study of healthy elderly men and women. Neurobiol Aging 1999;20(3):315-24.

141. Matthews K, Cauley J, Yaffe K, et al. Estrogen replacement therapy and cognitive decline in older community women. J Am Geriatr Soc 1999;47(5):518-23.

142. Jacobs DM, Tang MX, Stern Y, et al. Cognitive function in nondemented older women who took estrogen after menopause. Neurology 1998;50(2):368-73.

143. Resnick SM, Metter EJ, Zonderman AB. Estrogen replacement therapy and longitudinal decline in visual memory: a possible protective effect? Neurology 1997;49(6):1491-7.

144. Barrett-Connor E, Kritz-Silverstein D. Estrogen replacement therapy and cognitive function in older women. JAMA 1993;269(20):2637-41.

145. Funk JL, Mortel KF, Meyer JS. Effects of estrogen replacement therapy on cerebral perfusion and cognition among postmenopausal women. Dementia 1991;2(5):268-72.

146. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging [published erratum appears in Neurology 1998;51(2):654]. Neurology 1997;48(6):1517-21.

147. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348(9025):429-32.

148. Waring SC, Rocca WA, Petersen RC, et al. Postmenopausal estrogen replacement therapy and risk of AD: a population-based study. Neurology 1999;52(5):965-70.

149. Harwood DG, Barker WW, Loewenstein DA, et al. A cross-ethnic analysis of risk factors for Alzheimer's disease in white Hispanics and white non-Hispanics. Neurology 1999;52(3):551-6.

150. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 1996;156(19):2213-7.

151. Mortel KF, Meyer JS. Lack of postmenopausal estrogen replacement therapy and the risk of dementia. Journal of Neuropsychiatry & Clinical Neurosciences 1995;7(3):334-7.

152. Henderson VW, Paganini-Hill A, Emanuel CK, et al. Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol 1994;51(9):896-900.

153. Brenner DE, Kukull WA, Stergachis A, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study. Am J Epidemiol 1994;140(3):262-7.

154. Graves AB, White E, Koepsell TD, et al. A case-control study of Alzheimer's disease. Ann Neurol 1990;28(6):766-74.

155. Broe GA, Henderson AS, Creasey H, et al. A case-control study of Alzheimer's disease in Australia. Neurology 1990;40(11):1698-707.

156. Amaducci LA, Fratiglioni L, Rocca WA, et al. Risk factors for clinically diagnosed Alzheimer's disease: a case-control study of an Italian population. Neurology 1986;36(7):922-31.

157. Heyman A, Wilkinson WE, Stafford JA, et al. Alzheimer's disease: a study of epidemiological aspects. Ann Neurol 1984;15(4):335-41.

158. Petitti DB, Sidney S, Perlman J. Increased risk of cholecystectomy in users of supplemental estrogen. Gastroenterology 1988;94:91-5.

159. Coronary Drug Project. Gallbladder disease as a side effect of drugs influencing lipid metabolism. N Engl J Med 1977;296:1185-90.

160. Honore L. Increased incidence of symptomatic cholesterol cholelithiasis in perimenopausal women receiving estrogen replacement therapy. J Reprod Med 1980;25:187-90.

161. Everson R, Byar D, Bischoff A. Estrogen predisposes to cholecystectomy but not to stones. Gastronenterology 1982;82:4-8.

162. Kakar F, Weiss N, Strite S. Non-contraceptive estrogen use and the risk of gallstone disease in women. Am J Public Health 1988;78:564-6.

163. Jorgensen T. Gallstones in a Danish population: fertility period, pregnancies, and exogenous female hormones. Gut 1988;29:433-9.

164. Scragg R, McMichael A, Seamark R. Oral contraceptives, pregnancy and endogenous oestrogen in gall stone disease—a case-control study. BMJ 1984;288:1795-9.

165. Diehl A, Stern M, Ostrower V, et al. Prevalence of clinical gallbladder disease in Mexican-American, Anglo, and Black women. South Med J 1980;73:438-43.

166. Mamdani MM, Tu K, van Walraven C, et al. Postmenopausal estrogen replacement therapy and increased rates of cholecystectomy and appendectomy. Can Med Assoc J 2000;162(10):1421-4.

167. Lacey JJ, Mink P, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002;288(3):334-41.

168. Riman T, Dickman P, Nilsson S, et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 2002;94:497-504.

169. Rodriguez C, Patel A, Calle E, et al. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of U.S. women. JAMA 2001;285(11):1460-5.

170. Matthews KA, Kuller LH, Wing RR, et al. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 1996;143(10):971-8.

171. Derby CA, Hume AL, McPhillips JB, et al. Prior and current health characteristics of postmenopausal estrogen replacement therapy users compared with nonusers. Am J Obstet Gynecol 1995;173(2):544-50.

172. Persson I, Bergkvist L, Lindgren C, et al. Hormone replacement therapy and major risk factors for reproductive cancers, osteoporosis, and cardiovascular diseases: evidence of confounding by exposure characteristics. J Clin Epidemiol 1997;50(5):611-8.

173. Barrett-Connor E. Heart disease in women. Fertility & Sterility 1994;62(6 suppl 2):127S-32S.

174. Horwitz RI, Viscoli CM, Berkman L, et al. Treatment adherence and risk of death after a myocardial infarction. Lancet 1990;336(8721):1002-3.

175. Shumaker SA, Reboussin BA, Espeland MA, et al. The Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. Control Clin Trials 1998;19(6):604-21.

176. Wren BG. Mega-trials of hormonal replacement therapy. Drugs & Aging 1998;12(5):343-8.

Return to Contents

Notes

Author Affiliations

[a] Heidi D. Nelson, Linda L. Humphrey, Erin LeBlanc, Jill Miller, Lina Takano, Benjamin K.S. Chan, Peggy Nygren: Oregon Health & Science University, Portland, OR.
[b] Janet D. Allan, Steven M. Teutsch: U.S. Preventive Services Task Force.

Copyright Information

This document is in the public domain within the United States. For information on reprinting, contact Randie Siegel, Director, Division of Printing and Electronic Publishing, Agency for Healthcare Research and Quality, Suite 501, 2101 East Jefferson Street, Rockville, MD 20852. Requests for linking or to incorporate content in electronic resources should be sent to: info@ahrq.gov.

Return to Contents

Internet Citation:

Nelson HD, Humphrey LL, LeBlanc E, Miller J, Takano L, Chan BKS, Nygren P, Allan JD, Teutsch SM. Postmenopausal Hormone Replacement Therapy for Primary Prevention of Chronic Conditions. Summary of the Evidence for the U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/3rduspstf/hrt/hrtsum1.htm